Introduction
Alzheimer’s disease, death, AD
Alzheimer’s disease (AD) is the third leading cause of death among elderly persons in the United States and its prevalence is increasing, yet treatment options remain limited [Despite extensive preclinical analyses, knowledge on FUS-mediated BBB opening effects in live humans remains limited. Notably, species-specific differences in FUS effects have been reported due to structural and physiological variations of the brain, cranium, and cerebrovasculature across small and large animals [